CN113881623B - Method for forming ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic embryo - Google Patents
Method for forming ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic embryo Download PDFInfo
- Publication number
- CN113881623B CN113881623B CN202111169589.4A CN202111169589A CN113881623B CN 113881623 B CN113881623 B CN 113881623B CN 202111169589 A CN202111169589 A CN 202111169589A CN 113881623 B CN113881623 B CN 113881623B
- Authority
- CN
- China
- Prior art keywords
- cells
- parthenogenetic
- embryonic stem
- ovum
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a method for forming an ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic, which comprises the steps of treating strontium ions and cytochalasin D to obtain parthenogenetic activated embryos, establishing parthenogenetic embryonic stem cell lines, further differentiating to form primordial germ cell-like cells, and transplanting the primordial germ cell-like cells and mouse female embryonic gland cells into a combined immunodeficient mouse in a polymerization manner to obtain the ovum; the technology can produce infinite normal functional ova, and has important significance for clinically treating infertility or premature ovarian failure and obtaining enough high-quality ova in the scientific research process.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to a method for forming an ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenesis.
Background
Germ cells are the only cells in an organism that are capable of transmitting totipotency and genetic material of the organism by generational inheritance, including mature germ cells, i.e., sperm and eggs, that differentiate from Primordial Germ Cells (PGCs) to terminally differentiated. With the change of life style of human, the number of infertility patients increases year by year worldwide. It is important to understand human germ cells, including eggs and sperm. But is limited by the number and sampling difficulty of human ova and ethical constraints, and seriously hinders the research on the maturation mechanism of the ova and the improvement of the treatment level of clinical reproductive related diseases. Embryonic Stem Cells (ESCs) are plastic cells capable of self-renewal and differentiation potential, can be differentiated into two hundred or more cells and dozens of tissues and organs in animals, and have immeasurable significance in studying the basic laws of mammalian ontogeny, the principles of disease development and regenerative medicine application. The use of the pluripotency of embryonic stem cells to induce human embryonic stem cells (hESCs) into human ova in vitro has become a focus of the present research.
At present, there has been a report of using pluripotent stem cells to differentiate to form specific normal functional ova, which uses female Embryonic Stem Cells (ESCs) or female Induced Pluripotent Stem Cells (iPSCs) as starting cells to form primordial germ cell-like cells (PGCLCs) through a two-step differentiation method under the action of recombinant proteins and small molecular compounds. Differentiation of pluripotent stem cells into epiblast-like cells (EpiLCs) was performed in the first step by adding FGF2 and Activin a, and further by adding BMP4, LIF, SCF, and EGF, and differentiation of epiblast-like cells (EpiLCs) into primordial germ-like cells (PGCLCs) was performed under 3D culture conditions. The primordial germ-like cells (PGCLCs) are polymerized with mouse embryonic stage E12.5 female glandular cells and transplanted into combined immunodeficient mouse kidney cysts to form ova with normal fertilization capability.
However, this technique has the following major drawbacks in application:
1. embryonic stem cells and induced pluripotent stem cells have limitations in human applications.
The production of Embryonic Stem Cells (ESCs) necessarily destroys normal embryonic architecture and therefore has a strong ethical problem. And embryonic stem cells cannot be produced from the same individual, there is a risk of immunological rejection in future disease treatments and applications.
The formation process of most Induced Pluripotent Stem Cells (iPSCs) stimulates the endogenous gene expression of somatic cells by introducing exogenous genes, thereby reprogramming somatic cells into induced pluripotent stem cells. And the existence of the exogenous gene has certain tumorigenicity. In addition, induced pluripotent stem cells cannot be widely used because they accumulate genetic mutations during their formation, thereby causing genomic instability.
2. The process of pluripotent stem cell differentiation to form ova is often accompanied by incomplete erasure/reconstruction of genomic imprints, thereby reducing the efficiency of functional ova production.
The human genome is 2-fold, with half of the genome from the female parent and the other half from the male parent. In addition to carrying genetic information on DNA, maternal and paternal genomes also present genomic imprinting information dominated by DNA methylation. These genomic imprinting information is different in the maternal and paternal genomes, which can regulate normal gene expression. Embryonic stem cells are derived from fertilized embryos, while induced pluripotent stem cells are derived from reprogramming of individual somatic cells, and thus these cells all contain the paternal genome. During the process of forming primordial germ cells, the genomic imprints of paternal and maternal origin are erased, followed by reconstitution of the genomic imprints of maternal origin during the process of differentiation of primordial germ cells to form an egg.
3. In the process of forming the ovum by the human pluripotent stem cell, two X chromosomes of the formed human primordial germ cell-like cells are incompletely activated, so that the two X chromosomes cannot fully enter the meiosis process, and the ovum with normal function cannot be generated. Generally, the activity of X-staining from a parent source is lower than that of chromosomes from a parent source.
Parthenogenetic activation is the in vitro stimulation of oocytes in MII stage by physical and chemical means, resulting in the formation of pronuclei and development of embryos. The blastocyst obtained after Parthenogenetic activation of the oocyte is called a Parthenogenetic embryo, and an ICM is separated to establish an embryonic stem cell line called a Parthenogenetic embryonic stem cell (pESC) line. At present, no report on the differentiation of parthenogenetic embryonic stem cells into fully functional ova is available.
Disclosure of Invention
The invention aims to provide a method for forming an ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenesis, which aims to solve the problems in the prior art. The invention relates to a method for activating parthenogenesis of an ovum by using strontium ions and cytochalasin D, which is used for forming parthenogenetic embryonic stem cells (pESCs) with good developmental capacity and further differentiating the parthenogenetic embryonic stem cells to form the ovum. Parthenogenetic embryonic stem cells (pESCs) can be expanded indefinitely in vitro by cell culture methods, thus allowing unlimited cell sources. Further, an unlimited number of functional ova can be produced by cell differentiation techniques. The technology has important significance for clinically treating infertility or premature ovarian failure and obtaining sufficient high-quality ova in the scientific research process.
More importantly, the parthenogenetic embryonic stem cells (pESCs) can be obtained from the patient per se, and no exogenous gene is introduced in the parthenogenetic activation process, so that the restriction of ethical problems can be avoided, and the application risk is reduced to the minimum. Furthermore, because parthenogenetic embryonic stem cells (pESCs) are derived from an ovum, they do not have a genomic imprint of paternal origin, making it easier to complete erasure of the imprint during formation of primordial germ cell-like cells (PGCLCs) and to establish a genomic imprint of maternal origin suitable for an ovum. And parthenogenetic embryonic stem cell (pESCs) -derived primordial germ-like cells (PGCLCs) have two X chromosomes from maternal origin and should therefore more readily enter the meiotic process and form structurally and functionally normal ova.
In order to achieve the purpose, the invention provides the following scheme:
the invention provides a method for forming an ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic embryo, which comprises the following steps: treating the ovum with strontium ions and cytochalasin D to obtain parthenogenetic activated embryo, establishing parthenogenetic embryonic stem cell line, further differentiating to form primordial germ cell-like cells, and transplanting the primordial germ cell-like cells and mouse female embryonic glandular cells into a combined immunodeficient mouse in a polymerization manner to obtain the ovum.
Further, the method specifically comprises the following steps:
(1) Establishment of parthenogenetic embryonic stem cell line
In-vitro mouse MII phase ovum is adopted, granular cells are neutralized in HKSOM solution containing hyaluronidase, then the granular cells are cleaned in pure potassium ion optimized culture solution containing HEPES and sodium pyruvate, and the granular cells are transferred into parthenogenetic activation culture solution to be parthenogenetically activated;
cleaning the parthenogenetic activated embryos in the balanced KSOM and culturing until the embryos develop to blastula;
collecting blastocysts on a feeding layer treated by mitomycin C, adding a culture solution of a system building to culture until obvious outward growth can be seen;
collecting the outgrowth, digesting the outgrowth in trypsin, stopping digestion by using a stem cell culture solution, inoculating the outgrowth on a feeding layer treated by mitomycin C, and culturing and amplifying to obtain the parthenogenetic embryo stem cell line;
(2) Directed differentiation and sorting of primordial germ-like cells
Culturing the female embryonic stem cells and the parthenogenetic embryonic stem cells for 3-5 generations, and then starting induction; inoculating the female embryonic stem cells or parthenogenetic embryonic stem cells into a cell culture plate treated by the recombinant human fibronectin package, and culturing by using an EpiLC induction culture solution;
after the induction is finished, digesting the cells and counting, adopting PGCLCs to induce a differentiation culture solution for differentiation, and then adopting SSEA1-APC and CD61-PE direct standard antibodies for sorting to obtain primordial germ cell sample cells;
(3) Magnetic bead sorting of E12.5 female glandular cells
Digesting E12.5 day female gonads in TE, screening by a cell sieve and centrifuging; discarding the supernatant, using a magnetic bead antibody prepared by a magnetic bead sorting buffer solution to resuspend cells, and incubating on ice in a dark place; then, continuously washing and resuspending the cells by using a magnetic bead sorting buffer solution, and separating the cells to obtain E12.5-day female gonadal somatic cells with PGCs removed;
(4) In vitro repolymerization of repolymerized ovaries
Polymerizing the primordial germ cell-like cells obtained in the step (2) and the gonad somatic cells obtained in the step (3) according to the quantity ratio of 1;
(5) And (3) obtaining a combined immunodeficiency mouse, injecting the refocus ovary obtained in the step (4) into a kidney capsule of the combined immunodeficiency mouse, and culturing to obtain a normally functional ovum.
Further, the mass percent of HEPES in the pure potassium ion optimization culture solution containing HEPES and sodium pyruvate is 1%, and the concentration of the sodium pyruvate is 0.22g/mL.
Further, the parthenogenetic activation culture solution is Ca 2+ -free potassium ion-only optimized culture solution, 10mM SrCl 2 And 20. Mu.g/ml cytochalasin D.
Further, in the step (2), after the female embryonic stem cells and parthenogenetic embryonic stem cells are cultured for 3 to 5 passages in a culture system containing N2B27+ t2iL, induction is started when the cell state is good.
The invention discloses the following technical effects:
the method comprises the steps of differentiating parthenogenetic embryonic stem cells activated by strontium ions to form ova, namely treating the parthenogenetic activated embryos by the strontium ions and cytochalasin D to obtain parthenogenetic activated embryos, establishing parthenogenetic embryonic stem cell lines, further differentiating to form primordial germ cell-like cells, and transplanting the primordial germ cell-like cells and mouse E12.5 female embryo E12.5 sexual gland cells into a combined immunodeficient mouse in a polymerization manner to obtain the ova.
According to the parthenogenetic activation method, the parthenogenetic embryonic stem cells with high quality can be generated by combining strontium ions with cytochalasin D. Strontium ions can simulate the continuous calcium oscillation process in the fertilization process of the MII ovum, and the cytochalasin D can inhibit the discharge of the second polar body in the fertilization process of the MII ovum, so that the fully parthenogenetic-activated diploid embryo can be efficiently formed. The parthenogenetic activated diploid embryo has the capacity of developing into a blastula similar to that of a normal fertilized embryo, the blastula can form parthenogenetic embryonic stem cells (pESCs) through embryo establishment, and the parthenogenetic embryonic stem cells (pESCs) have the same quality and development potential as those of normal mouse Embryonic Stem Cells (ESCs).
Parthenogenetic embryonic stem cells (pESCs) differentiate to form primordial germ cell-like cells (PGCLCs) that have similar levels of gene expression and methylation to normal Primordial Germ Cells (PGCs) in vivo, and can also be fertilized in vitro to obtain healthy, fertile mouse offspring.
By using the method, a high-quality parthenogenetic embryonic stem cell (pESCs) cell line can be generated by 16 MII ova on average. When parthenogenetic embryonic stem cells (pESCs) are expanded in vitro for 10 generations, 2.4X 10 can be obtained by differentiation 6 One ovum (on average each MII ovum can be amplified to obtain 1.5X 10 5 Individual eggs).
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.
FIG. 1 is a schematic diagram of the process of in vitro differentiation of an ovum from a parthenogenetic embryonic stem cell line.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but rather as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The description and examples are intended to be illustrative only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including but not limited to.
Example 1
(1) Establishment of parthenogenetic embryonic stem cell (pESCs) line
a. Injecting 5IU of Pregnant Mare Serum Gonadotropin (PMSG) into the abdominal cavity of each female mouse with 6-8 weeks old Actin-GFP, and injecting 5IU of Human chorionic gonadotropin (hCG) into the abdominal cavity of each mouse for superovulation 46-48h after injection;
b. 14h after hCG injection, MII ova were collected from the oviduct and granular cells were digested in a preheated HKSOM solution containing 0.3% hyaluronidase, then washed 3 times in a preheated Potassium-only optimized medium (Potasus simple-timed medium conditioning HEPES and sodium bicarbonate, HKSOM) solution containing 1% HEPES and 0.22g/ml sodium pyruvate, transferred to 50. Mu.l of estrus soliquous activation medium, activated for 4h in an incubator, and 2 prokaryotes were observed after the estrus soliquous activation (formulation of the estrus soliquous activation medium: ca: H) 2+ -free simple Potassium-optimized medium (KSOM) +10mM SrCl 2 +20μg/ml cytochalasin D)；
KSOM Stock 10X ingredients are as follows:
KSOM 50ml fraction as follows:
HKSOM 50ml has the following composition:
c. cleaning the parthenogenetic activated embryos in the balanced KSOM for 3 times, culturing the parthenogenetic activated embryos in the KSOM, observing 2-cell embryos the next day, taking out and discarding embryos which do not grow to 2 cells, and allowing the remaining embryos to grow to blastula;
d. inoculating the blastocyst onto a 20. Mu.g/ml mitomycin C treated feeder layer (4-well plate), adding a culture medium (knockkout DMEM medium +20% KSR +1mM L-glutamine +1% non-essential amino acids +50units/ml penicillin +50mg/ml streptomycin +0.1mM 2-mercaptoethanol +1mM PD0325901+1000IU/ml LIF) to culture, changing the medium every other day, and generating a remarkable outward growth (outgrowth) after culturing for 7 days;
e. the growths were picked up with a 10. Mu.l pipette tip, digested for 5min in 0.25% trypsin, then digested with dry cell culture medium (knockkout DMEM medium +15% FBS +1mM L-glutamine +1% nonessential amino acids +50units/ml penicillin +50mg/ml streptomycin +0.1mM 2-mercaptoethanol +1000IU/ml LIF), and inoculated on mitomycin C treated feeder layers for culture and amplification, using pronuclear karyotyping.
(2) Directed differentiation and sorting of primordial germ-like cells (PGCLCs)
a. Culturing ESCs and pESCs in a culture system of N2B27+ t2iL (1000 IU/ml LIF, 1mM PD0325901 and 3mM CHIR99021) for 3-5 generations, and starting to induce PGCLCs when the cell state is good;
b. inoculating ESCs or pESCs into a cell culture plate coated with recombinant human Fibronectin (hFN), culturing for 2d with EpiLC induction medium (N2B 27 medium +20ng/ml activin A + bFGF +1% KSR), and replacing fresh EpiLC culture medium every day;
c. after EpiLC induction for 2d, digesting the cells, after counting the cells, inducing differentiation medium (GMEM medium +15% KSR +1mM sodium pyruvate +1mM L-glutamine +1% non-essential amino acids +50units/ml penicillin +50mg/ml streptomycin +0.1mM 2-mercaptoethanol +500ng/ml BMP4+1000IU/ml mLIF +100ng/ml SCF +50ng/ml EGF) using PGCLCs, and culturing by inoculating the cells in low adhesion 96-well plates per Embryoid body (Embryoid bodies, EB, EBs) according to 3000 cells;
d. after differentiation of PGCLCs for 4d, sorting was performed by Flow cytometric sorting (FACS) using SSEA1-APC and CD61-PE direct labeled antibodies.
(3) Magnetic bead sorting of E12.5 female glandular cells
a. Isolating E12.5 day gonads and digesting them in 0.25% TE buffer for 10min at 37 ℃;
b. after digestion is stopped, the mixture is sieved by a 40-micron cell sieve and centrifuged for 5min at 300 g;
c. discarding the supernatant, resuspending the cells with magnetic bead antibody prepared with 100. Mu.l of magnetic bead sorting buffer, incubating for 20min on ice in the dark, installing a magnetic frame during the incubation, and balancing the adsorption column with 1ml of magnetic bead sorting buffer;
d. after washing the cells with 4ml of magnetic bead sorting buffer, resuspending the cells with 1ml of magnetic bead sorting buffer, and gently adding the cell suspension to an adsorption column, taking care not to generate air bubbles, and collecting the remaining liquid with a 1.5ml EP tube;
e. centrifuging the liquid, removing supernatant, precipitating to remove PGCs, and resuspending with appropriate amount of culture solution.
(4) In vitro repolymerization and meiosis induction of repolymerized ovaries
a. Polymerizing gonadal somatic cells separated from magnetic beads and PGCLCs sorted by a flow cytometer in a low-adhesion 96-well culture plate according to the ratio of 1;
b. after culturing the refocused ovaries in vitro for 24h, injecting the refocused ovaries into NOD-SCID mouse kidney cysts for neutralization sampling detection, collecting the refocused ovaries on 25-28 days of injection for tissue section, and observing mature follicles wrapped by multiple layers of granular cells, wherein the follicles are provided with follicle cavities, and the diameter of the ovaries is 50-100 mu m;
c. for the relevant samples for meiosis detection, 3 μ M all-trans Retinoic Acid (RA) was added to the refolding culture solution for refolding, and the subsequent operations were the same as those of the normal samples.
(5) Renal cyst transplantation
a. Using NOD-SCID mice of 4-6 weeks old and anaesthetizing before operation, wherein general anaesthesia can be maintained for 20-30min for enough time to transplant;
b. the mice are placed on the side, and the refocus ovary is injected into the kidney cyst of the mice, and the whole process does not exceed 10min.
(6) In vitro maturation and in vitro fertilization
a. In vitro maturation solution (a-MEM culture)Nutrient base +5% FBS +0.24mM sodium pyruvate +1IU/ml PMSG +1.5IU/ml hCG) 5% CO in advance at 37 ℃% 2 Equilibrating in a warm bath incubator for 30min (unscrewing the lid), and preparing 35mm dish in vitro maturation solution (using 35mm Petri-dish, spot 7 drops of 50. Mu.l in vitro maturation solution, cover it with 3ml mineral oil, CO 2 Equilibrating the culture for at least 2 h);
b. taking out ovum with normal function from mouse kidney cyst, selecting ovum with normal shape, placing in IVM culture drop, and adding CO 2 Culturing in an incubator for 6-7h to reach meiosis Metaphase (MI), and culturing for 10h (16-17 h in total) to reach MII metaphase;
c. preparing a pseudopregnant mouse one day in advance, and detecting thrombus on the day of fertilization, and recording as E0.5; one day ahead 1 fertilization drop was made (90. Mu.l/drop, 5 drops/dish in 35mm Pteri-dish, covered with 3ml mineral oil, drops not well over round) and 2 KSOM embryo culture drops or G1-Plus embryo culture drops (7 drops of 50. Mu.l) were made, equilibrated overnight;
d. killing male mouse 2h before taking ovum, painlessly according to standard ethical operation, taking epididymis tail in 35mm Petri-dish with 2ml HTF receiving sperm, obtaining sperm from epididymis, microscopic examination, if the sperm swims fast, the quality is good, controlling the concentration of the sperm at about 5X 10 6 Per ml;
e. putting MII ovum obtained by in vitro maturation into fertilization drop (about 20 ovum/drop), adding 20 μ l of supernatant fluid, and fertilizing in incubator for 6h;
f. washing with preheated semen for 2 times, washing ovum with preheated KSOM or G1-Plus embryo culture solution for 3 times, culturing in KSOM or G1-Plus embryo culture solution drop, and washing to prevent residual sperm from affecting the development of fertilized embryo;
g. the next day, embryos that entered the 2-cell stage were picked and placed into KSOM culture drops for culture or direct transfer, and if unfertilized or dead embryos were present in the culture drops, the overall quality of the embryo development would be affected.
As shown in figure 1 and the following table, the method can be used for generating a high-quality parthenogenetic embryonic stem from 16 MII eggs on averageCell (pESCs) cell lines. When parthenogenetic embryonic stem cells (pESCs) are expanded in vitro for 10 generations, 2.4X 10 can be obtained by differentiation 6 One ovum (on average each MII ovum can be amplified to obtain 1.5X 10 5 Individual eggs).
Second step amplification of pESC
Third step, PGCLCs induction
Fourth step reoccumulation of ovarian formation (each polymer contains 2X10 4 PGCLCs and 10x10 4 Female gland cell)
The fifth step is the GV ovum number of each reunion ovary
The above-described embodiments are only intended to illustrate the preferred embodiments of the present invention, and not to limit the scope of the present invention, and various modifications and improvements made to the technical solution of the present invention by those skilled in the art without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.
Claims (1)
1. A method for forming an ovum by in vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenesis comprises the following steps: treating the ovum with strontium ions and cytochalasin D to obtain parthenogenetic activated embryo, establishing parthenogenetic embryonic stem cell line, further differentiating to form primordial germ cell-like cells, and transplanting the primordial germ cell-like cells and female embryonic glandular cells of a mouse into a combined immune defective mouse in a polymerization manner to obtain the ovum;
the method specifically comprises the following steps:
(1) Establishment of parthenogenetic embryonic stem cell line
In-vitro mouse MII stage ovum is digested into granular cells in HKSOM solution containing hyaluronidase, then washed in pure potassium ion optimized culture solution containing HEPES and sodium pyruvate, transferred into parthenogenetic activation culture solution, and parthenogenetic activation is carried out; cleaning the parthenogenetic activated embryos in the balanced KSOM and culturing until the embryos develop to blastula; collecting blastocysts on a feeding layer treated by mitomycin C, adding a culture solution of a system building to culture until obvious outward growth can be seen; collecting the outgrowth, digesting the outgrowth in trypsin, stopping digestion by using a stem cell culture solution, inoculating the outgrowth on a feeding layer treated by mitomycin C, and culturing and amplifying to obtain the parthenogenetic embryo stem cell line; the mass percent of HEPES in the pure potassium ion optimization culture solution containing HEPES and sodium pyruvate is 1%, and the concentration of the sodium pyruvate is 0.22g/mL; the parthenogenetic activation culture solution is Ca 2+ -free Potassium ion simple optimization culture solution, 10mM SrCl 2 And 20 μ g/ml cytochalasin D;
(2) Directed differentiation and sorting of primordial germ-like cells
Culturing the female embryonic stem cells and the parthenogenetic embryonic stem cells in a culture system containing N2B27+ t2iL for 3-5 generations, and then starting to induce when the cell state is good; inoculating the female embryonic stem cells or the parthenogenetic embryonic stem cells into a cell culture plate treated by the recombinant human fibronectin, and culturing by using an EpiLC induction culture solution; after induction is finished, digesting cells and counting, adopting PGCLCs to induce a differentiation culture solution to differentiate, and then adopting SSEA1-APC and CD61-PE direct standard antibodies to sort to obtain primordial germ cell sample cells;
(3) Magnetic bead sorting of E12.5 female glandular cells
Digesting E12.5 day female gonads in TE, screening by using a cell sieve and centrifuging; discarding the supernatant, resuspending cells by using a magnetic bead antibody prepared by a magnetic bead sorting buffer solution, and incubating on ice in a dark place; then, continuously washing, resuspending and separating by using a magnetic bead sorting buffer solution to obtain E12.5-day female gonad somatic cells with PGCs removed;
(4) In vitro repolymerization of repolymerized ovaries
Polymerizing the primordial germ cell-like cells obtained in the step (2) and the gonad somatic cells obtained in the step (3) according to the number ratio of 1;
(5) And (3) obtaining a combined immunodeficiency mouse, injecting the refocus ovary obtained in the step (4) into a kidney capsule of the combined immunodeficiency mouse, and culturing to obtain a normally functional ovum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111169589.4A CN113881623B (en) | 2021-10-08 | 2021-10-08 | Method for forming ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic embryo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111169589.4A CN113881623B (en) | 2021-10-08 | 2021-10-08 | Method for forming ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic embryo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113881623A CN113881623A (en) | 2022-01-04 |
| CN113881623B true CN113881623B (en) | 2022-11-22 |
Family
ID=79005278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111169589.4A Active CN113881623B (en) | 2021-10-08 | 2021-10-08 | Method for forming ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic embryo |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113881623B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008263815A (en) * | 2007-04-18 | 2008-11-06 | Institute Of Physical & Chemical Research | Activation of ovum using chelating agent |
| CN101735978A (en) * | 2009-12-29 | 2010-06-16 | 中山大学 | In-vitro maturation culture method for oocyte of mouse and method for establishing parthenogenetic embryonic stem cell line |
| CN110724725A (en) * | 2019-10-30 | 2020-01-24 | 南通大学 | Method for evaluating influence of smoking on oocyte quality |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014133194A1 (en) * | 2013-03-01 | 2014-09-04 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to germ cells |
-
2021
- 2021-10-08 CN CN202111169589.4A patent/CN113881623B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008263815A (en) * | 2007-04-18 | 2008-11-06 | Institute Of Physical & Chemical Research | Activation of ovum using chelating agent |
| CN101735978A (en) * | 2009-12-29 | 2010-06-16 | 中山大学 | In-vitro maturation culture method for oocyte of mouse and method for establishing parthenogenetic embryonic stem cell line |
| CN110724725A (en) * | 2019-10-30 | 2020-01-24 | 南通大学 | Method for evaluating influence of smoking on oocyte quality |
Non-Patent Citations (6)
| Title |
|---|
| Birth of Parthenote Mice Directly from Parthenogenetic Embryonic Stem Cells;Zhisheng Chen等;《Stem Cells》;20090619;第27卷;全文 * |
| Functional Oocytes Derived from Granulosa Cells;Chenglei Tian等;《Cell Reports》;20191224;第29卷;第4256页"Summary"，第e5页"Kidney Capsule Transplantation"、"In Vitro Maturation and In Vitro Fertilization" * |
| Generation of developmentally competent oocytes and fertile mice from parthenogenetic embryonic stem cells;Chenglei Tian等;《Protein&Cell》;20211130;第12卷(第12期);全文 * |
| Germline competency of parthenogenetic embryonic stem cells from immature oocytes of adult mouse ovary;Zhong Liu等;《Human Molecular Genetics》;20110114;第20卷(第7期);第1339页"Abstract"，第1348页"Fertilized embryos and parthenogenetic ‘embryos’"，第1342页Figure 2，第1343页Figure 3、Table 1，第1348页"Fertilized embryos and parthenogenetic ‘embryos’"、"Isolation and culture of ES cells and IVM pESCs" * |
| Offspring from Oocytes Derived from in Vitro Primordial Germ Cell–like Cells in Mice;Katsuhiko Hayashi等;《Science》;20121116;第338卷;全文 * |
| 小鼠胚胎干细胞系的建立及向雌性生殖细胞诱导的研究;曾明等;《南开大学学报（自然科学版）》;20180220;第51卷(第1期);第1页摘要，第2-3页"1.3 小鼠胚胎干细胞系的建立以及性别鉴定"、"1.5 原始生殖细胞样细胞诱导分化"、"1.6 重聚卵巢的移植及减数分裂的检测"，第6页"3 讨论"，第2页"1.2.1 试剂配制" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113881623A (en) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6905714B2 (en) | Culture method for differentiating primordial germ cells into functionally mature oocytes | |
| US9476064B2 (en) | Neuro-progenitor produced from an SCNT-derived ES cell | |
| US6107543A (en) | Culture of totipotent embryonic inner cells mass cells and production of bovine animals | |
| EP1149898A2 (en) | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals | |
| Desmarais et al. | Trophoblast stem cell marker gene expression in inner cell mass-derived cells from parthenogenetic equine embryos | |
| WO1995016770A1 (en) | Ungulate preblastocyst derived embryonic stem cells and use thereof to produce cloned transgenic and chimeric ungulates | |
| AU699869B2 (en) | EG Cells of Ungulates | |
| EP1293561B1 (en) | Monkey-origin embryonic stem cells | |
| CN113881623B (en) | Method for forming ovum by in-vitro differentiation of parthenogenetic embryonic stem cells activated by parthenogenetic embryo | |
| US20170088816A1 (en) | Mammalian embryonic stem cell isolated from a homogeneous pluripotent outgrowth of a mammalian pre-implantation embryo | |
| Lü et al. | Bioreactor cultivation enhances NTEB formation and differentiation of NTES cells into cardiomyocytes | |
| Bongso et al. | Human blastocyst culture and derivation of embryonic stem cell lines | |
| WO2013159313A1 (en) | Animal embryonic stem cell line, and preparation method and application thereof | |
| CN101886059A (en) | Culture solution used for embryo vitro production and method for bovine embryo vitro production | |
| JP2005523685A (en) | Somatic embryonic stem cells and their differentiated progeny | |
| Lee et al. | Establishment of a basic method for manipulating preantral follicles: effects of retrieval method on in vitro growth of preantral follicles and intrafollicular oocytes | |
| Nagy et al. | Development of artificial gametes | |
| WO2006083133A2 (en) | Human embryonic stem cell created from an oocyte and a somatic cell derived from non-identical individuals and a method for preparing the same | |
| Gong et al. | Derivation of histocompatible stem cells from ovarian tissue | |
| WO2024030443A1 (en) | Bovine blastocyst like structures and uses thereof | |
| Shetty | Stem Cell Technologies for Generating Cells and Organs for Regenerative Medicine | |
| CN114369567A (en) | Method for establishing bovine expanded pluripotent embryonic stem cells and culture solution | |
| KR100544922B1 (en) | Method of Constructing Gene Manipulation Animal and Clone Animal | |
| CN118185862A (en) | Preparation method of mouse tetraploid organ | |
| Shimozawa et al. | Reproductive technologies and related studies in the cynomolgus monkey |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |